Oramed Pharmaceuticals Inc (ORMP)
$2.46
+0.16
(+6.96%)▲
Insights on Oramed Pharmaceuticals Inc
Decreasing Revenue
Revenue is down for the last 4 quarters, 682.0K → 674.0K (in $), with an average decrease of 0.4% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -3.22M → 13.33M (in $), with an average increase of 124.2% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 52.5% return, outperforming this stock by 49.4%
Performance
- $2.31$2.48$2.46
6.1%
Downside
Day's Volatility :6.85%
Upside
0.81%
- $1.67$5.25$2.46
32.11%
Downside
52 Weeks Volatility :68.19%
Upside
53.14%
Returns
| Period | Oramed Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -0.86% | 0.5% | 0.0% |
6 Months | 25.0% | 11.7% | 0.0% |
1 Year | 3.14% | 6.2% | 2.2% |
3 Years | -80.29% | 13.5% | -23.0% |
Highlights
Market Capitalization | 96.0M |
Book Value | $4.06 |
Earnings Per Share (EPS) | 0.14 |
PE Ratio | 16.93 |
PEG Ratio | 0.0 |
Wall Street Target Price | 4.25 |
Profit Margin | 412.31% |
Operating Margin TTM | -1176.79% |
Return On Assets TTM | -5.16% |
Return On Equity TTM | 3.24% |
Revenue TTM | 1.3M |
Revenue Per Share TTM | 0.03 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 2.7M |
EBITDA | -15.6M |
Diluted Eps TTM | 0.14 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.31 |
EPS Estimate Next Year | -0.26 |
EPS Estimate Current Quarter | -0.08 |
EPS Estimate Next Quarter | 0.02 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 72.76%
Technicals Summary
Sell
Neutral
Buy
Oramed Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Oramed Pharmaceuticals Inc | -15.44% | 25.0% | 3.14% | -80.29% | -80.29% |
 Moderna, Inc. | -1.15% | 39.75% | -18.77% | -40.22% | 304.34% |
 Regeneron Pharmaceuticals, Inc. | -7.56% | 12.46% | 14.48% | 77.72% | 159.17% |
 Novo Nordisk A/s | -2.8% | 32.13% | 52.48% | 239.51% | 414.16% |
 Vertex Pharmaceuticals Incorporated | -4.96% | 10.08% | 23.01% | 83.3% | 130.08% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Oramed Pharmaceuticals Inc | 16.93 | 16.93 | 0.0 | -0.31 | 0.03 | -0.05 | NA | 4.06 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Oramed Pharmaceuticals Inc | Hold | $96.0M | -80.29% | 16.93 | 412.31% |
Moderna, Inc. | Buy | $41.7B | 304.34% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 159.17% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 414.16% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 130.08% | 28.81 | 36.68% |
Institutional Holdings
BML Capital Management LLC
3.13%Murchinson Ltd.
2.60%BOOTHBAY FUND MANAGEMENT, LLC
1.30%Renaissance Technologies Corp
0.85%Rathbone Brothers PLC
0.72%Two Sigma Advisers, LLC
0.70%
Company Information
oramed pharmaceuticals (nasdaqcm:ormp) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 trials under the usfda, the company is seeking to revolutionize the treatment of diabetes. read more: http://www.oramed.com/investors/corporate-presentation watch: https://www.youtube.com/watch?v=5qchxtdv9eg
Organization | Oramed Pharmaceuticals Inc |
Employees | 0 |
CEO | Mr. Nadav Kidron Esq. |
Industry | Health Technology |
